Skip to menu Skip to content Skip to footer

2025

Journal Article

Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern

Suo, Paulina, Srinivasan, Ashish, Thin, Lena, An, Yoon‐Kyo, Fernandes, Richard G., Ghaly, Simon, Jeffrey, Angus W., Menon, Shankar, Olsen, Nicholas, Skinner, Thomas, van Langenberg, Daniel R., Winston, James and Haifer, Craig (2025). Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. Journal of Gastroenterology and Hepatology. doi: 10.1111/jgh.16916

Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern

2025

Journal Article

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report

Huynh, David, Khaing, Myat Myat, Fernandes, Richard Gareth, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2025). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Reports in Gastroenterology, 19 (1), 1-6. doi: 10.1159/000542711

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report

2024

Journal Article

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Gilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2024). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. doi: 10.5217/ir.2024.00127

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

2023

Journal Article

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

2022

Journal Article

Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?

Fernandes, Richard G. and Radford-Smith, Graham (2022). Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?. Alimentary Pharmacology & Therapeutics, 55 (10), 1350-1351. doi: 10.1111/apt.16905

Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?